Renal cancer biomarkers of angiogenesis in renal cell carcinoma (RCC): a multicentre, prospective, non-randomised, observational study

Cambridge University Hospitals NHS Foundation Trust0 个研究点目标入组 80 人开始时间: 2011年2月7日最近更新: 2021年9月20日

适应症

试验速览

暂无简介。

•1. Newly diagnosed histologically or cytologically confirmed renal cell carcinoma with a clear cell component; patients who have a radiological diagnosis of probable renal cell carcinoma can be included whilst still awaiting biopsy or surgery and once confirmed to have clear cell renal cell carcinoma, they will be included in the study. If their histology confirms a non-clear cell renal cell carcinoma, they will be replaced.
•2. Metastatic renal cell carcinoma with a clear cell component with previous nephrectomy but with no previous history of use of systemic therapy with the exception of immunotherapy, provera and bisphosphonates. Prior palliative radiotherapy is permitted.
•3. Ability and willingness to provide written informed consent
•4. Ability and willingness to co-operate with study procedures, including blood and urine sampling
•5. Aged greater than or equal to 18 years, either sex

•1. Previous history of cancer other than RCC, autoimmune diseases or known active infection
•2. Previous history of use of systemic therapy for treatment of renal cell carcinoma other than immunotherapy, provera and bisphosphonates. Prior palliative radiotherapy is not an exclusion criterion.
•3. Patients who commence therapy in between study visits (sample collection); although if the first sample is already collected before starting treatment, then that sample will be processed and the second sample will not be collected
•4. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, HBV and HCV

发起方